Name

Œdème maculaire post-vitrectomie pour décollement de rétine rhegmatogene

 To report the incidence, visual outcomes and management of post-surgical macular edema following pars plana vitrectomy for rhegmatogenous retinal detachment, over a 3-year period from 01/09/2015 to 01/09/2018 in a university hospital center.

The database of medical records were consulted for records of all patients who underwent pars plana vitrectomy for retinal detachment who were subsequently diagnosed with a post-surgical macular edema (PSME) on spectral domain optical coherence tomography (SD-OCT) in the 6 months postoperative period.

The incidence of post-vitrectomy macular edema in RRD following vitrectomy in our center was found to be quite low at (2.07%)

Known therapeutic management of post-surgical macular edema such as in cases of Irvine-Gass syndrome by topical nonsteroidal anti-inflammatory drugs (NSAIDs), topical corticosteroids, a carbonic anhydrase inhibitor or the intravitreal injection of dexamthasone implant (Ozurdex) are shown to be safe and useful therapeutic treatment. 

The incidence of post-vitrectomy macular edema in RRD following surgical repair in our center was found to be rare at 2.07%, known therapeutic management of postsurgical macular edema such as in cases of Irvine-Gass syndrome are shown to be useful.